StockData
VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30

VERU INC.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.31+0.01 (+0.43%)

Close on Oct 19, 2026

Market cap
$53.25M
P/E (TTM)
–
Dividend yield
–

VERU INC. revenue by segment

By business segment

By product or service

RevenueTTM Q4 24TTM Q3 24TTM Q2 24TTM Q1 24TTM Q4 23TTM Q3 23TTM Q2 23TTM Q1 23TTM Q4 22TTM Q3 22TTM Q2 22TTM Q1 22% of revenueYoY
FC2 Female Condom [Member]$16.89M–––$16.28M–––––––100.0%+3.7%
FC2, U.S. Prescription Channel [Member]––$2.75M$6.29M$5.82M$5.49M$11.37M$18.81M$30.22M–––––
FC2, Global Public Health Sector [Member]––$10.73M$9.63M$10.46M$9.51M$9.90M$8.90M$9.13M–––––
FC2 [Member]––$13.48M$15.92M$16.28M$15.01M$21.27M$27.72M$39.35M–––––

By region

RevenueTTM Q4 24TTM Q3 24TTM Q2 24TTM Q1 24TTM Q4 23TTM Q3 23TTM Q2 23TTM Q1 23TTM Q4 22TTM Q3 22TTM Q2 22TTM Q1 22% of revenueYoY
United States$5.35M$5.02M$5.37M$8.92M$8.37M$7.70M$13.27M$20.33M$31.43M$44.67M$51.73M$50.49M37.9%-36.0%
Other Geographical Areas [Member]$4.70M–––$5.99M–––––––33.2%-21.5%
Mozambique$2.17M–––––––––––15.4%–
South Africa$1.90M–––$1.94M–––––––13.5%-2.0%
Other Countries [Member]––$5.47M$5.07M$5.99M$5.13M$6.43M$7.14M$7.92M$7.74M$8.74M$10.29M––

From the segment and revenue-disaggregation notes of VERU's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.